Essential Thrombocythemia Market

The total prevalent population of Essential Thrombocythemia (ET) in 2017 was 232,688 in the seven major markets.

With 142,635 cases in 2017, the United States registered the highest prevalent population of Essential Thrombocythemia among the 7MM. Out of all the cases in the United States (in 2017), it is being observed that the age-group of 60-80 years accounted for the highest cases of Essential Thrombocythemia.

The market size of Essential Thrombocythemia (ET) was found to be USD 616.05 Million in 2017, which is expected to increase during the forecast period 2017-2030.

The key players in the Essential Thrombocythemia Market includes PharmaEssentia, Eli Lilly and Company, Novartis, Geron Corporation, Italfarmaco, Imago BioSciences, Galena Pharma, and many others.

For more details visit: https://www.delveinsight.com/report-store/essential-thrombocythemia-et-market-insights